Loading…
Based on limited metadata, Essnd Global received an FDA Warning Letter on February 14, 2020, regarding drug products. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The warning falls under FDA's drug product oversight authority, though the specific issuing office is not documented in this metadata. To understand the precise compliance issues cited, review of the complete Warning Letter would be necessary.